PRO-C17
A fragment of the ectodomain of type XVII collagen, enabling non-invasive monitoring of epithelial damage and basement membrane remodeling in skin and gastrointestinal disorders.
Key features and values
- Quantifies ectodomain fragments of type XVII collagen indicative of epithelial damage.
- Reflects basement membrane remodeling associated with skin and gastrointestinal disorders.
- Provides a non-invasive measure of epithelial tissue turnover.
- Supports monitoring of disease progression and response to therapies targeting epithelial integrity.
- Applicable in research on diseases characterized by aberrant epithelial remodeling, such as atopic dermatitis and colorectal cancer.
- Facilitates evaluation of interventions aimed at modulating epithelial damage and repair.
- Complements other biomarkers for a comprehensive assessment of epithelial tissue dynamics.
Description
The PRO-C17 biomarker assay measures specific fragments of the ectodomain of type XVII collagen, serving as an indicator of epithelial damage and basement membrane remodeling. This non-invasive assay provides insights into epithelial tissue turnover processes associated with skin and gastrointestinal disorders. By quantifying type XVII collagen degradation products, the PRO-C17 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of epithelial damage and repair. It serves as a valuable tool in research settings for assessing the dynamics of epithelial tissue remodeling.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
